Regeneron Pharmaceuticals, Inc. (regn)
REGN — Company Overview
Regeneron Pharmaceuticals, Inc. (REGN) trades on NMS as part of the Healthcare peer group (Biotechnology).
| Ticker | REGN |
| Sector | Healthcare |
| Industry | Biotechnology |
| Exchange | NMS |
| Market cap | $82.55B |
| Last price | $801.82 |
| Size category | Large Cap |
REGN — Business Description
REGN represents a Biotechnology business in the Healthcare segment. Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat hete…
Official website: https://www.regeneron.com.
REGN — Investment Thesis
At a high level, REGN offers exposure to Healthcare with metrics outlined below from public market data.
- Revenue is expanding at roughly 16.7% year-over-year (public data).
- Trailing P/E of 19.88× sits in a moderate band relative to high-growth peers.
- Forward P/E (13.17×) is below trailing P/E — earnings may be expected to improve.
- Equity market capitalization is approximately $82.55B.
See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.
REGN — Financial Health
Key financial health indicators for Regeneron Pharmaceuticals, Inc. are derived exclusively from public data — no proprietary estimates.
Profit margin of 27.9% indicates solid bottom-line conversion. Positive free cash flow of $3.07B supports balance-sheet flexibility.
| Trailing P/E | 19.88× |
| Forward P/E | 13.17× |
| Price / Sales | 5.31× |
| Price / Book | 2.54× |
| Gross margin | 44.5% |
| Operating margin | 33.1% |
| Profit margin | 27.9% |
| Return on equity | 14.0% |
| Debt / Equity | 8.54 |
| Free cash flow | $3.07B |
REGN — Growth Outlook
Growth outlook for Regeneron Pharmaceuticals, Inc. (REGN) depends on demand trends in Biotechnology and the company's ability to convert revenue into sustainable earnings.
- Revenue growth of 16.7% indicates strong top-line momentum.
- Earnings declined -4.5% year-over-year — margin or volume pressure may be in play.
- Price is 6.7% below the 52-week high.
REGN — Competitive Position
Regeneron Pharmaceuticals, Inc. (REGN) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.
- Competes within Healthcare, specifically in Biotechnology.
- Market capitalization of $82.55B places REGN among large-cap peers.
- Gross margin near 44.5% may reflect pricing power or favorable mix.
REGN — Strengths
Strengths for Regeneron Pharmaceuticals, Inc. (REGN) inferred from public financial metrics:
- Revenue growth of 16.7% year-over-year.
- Gross margin of 44.5% supports competitive unit economics.
- Positive free cash flow ($3.07B).
- Moderate leverage (debt/equity 8.54).
- Large Cap scale ($82.55B) may provide distribution and funding advantages.
- Price near 52-week highs — positive price momentum on public markets.
REGN — Weaknesses
Weaknesses and pressure points for Regeneron Pharmaceuticals, Inc. (REGN) based on available data:
- Earnings decline of -4.5% year-over-year.
REGN — Opportunities
- Sustained revenue growth (16.7%) could support multiple expansion if margins hold.
- Positive free cash flow enables reinvestment, debt reduction, or shareholder returns.
- Forward earnings multiple below trailing P/E — potential earnings acceleration ahead.
REGN — Risks
- Standard market, regulatory, competitive, and execution risks apply to all public equities.
REGN — Summary
Regeneron Pharmaceuticals, Inc. (REGN) is a large-cap Healthcare company focused on Biotechnology, listed on NMS. Last price $801.82 with market cap $82.55B. Trailing P/E 19.88×. Revenue grew 16.7% year-over-year per public data. Notable strengths include revenue growth of 16.7% year-over-year. Key watch items include earnings decline of -4.5% year-over-year. Premium Terminal tools for Regeneron Pharmaceuticals, Inc. add ownership analytics, news, and richer estimate history beyond this public summary.
Start Free — open REGN in Vest Terminal
Access live data, filings, ownership, and analysis for Regeneron Pharmaceuticals, Inc..
Regeneron Pharmaceuticals, Inc. FAQ
What does Regeneron Pharmaceuticals, Inc. (REGN) do?
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and…
What is REGN's P/E ratio?
Regeneron Pharmaceuticals, Inc. has a trailing P/E of 19.88× based on publicly available market data.
Does REGN pay a dividend?
Indicated dividend yield: 0.5%. Confirm ex-dates and payout history in Vest Terminal.
What sector is REGN in?
Regeneron Pharmaceuticals, Inc. is classified in Healthcare (Biotechnology) on NMS.
What is REGN's market capitalization?
Approximate market cap: $82.55B.
What are the main risks for REGN?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of REGN?
Potential positives include revenue growth of 16.7% year-over-year, gross margin of 44.5% supports competitive unit economics.
Where can I get analyst estimates for REGN?
Public analyst price targets and consensus for Regeneron Pharmaceuticals, Inc. are on the free /stocks/regn/estimates page. Deeper estimate history and models are available in Vest Terminal.